Expleo Solutions Ltd
EXPLEOSOLExpleo Solutions Ltd's earnings have outrun its stock. EPS grew +20.1% in a year against a −31.1% price move.
The sharpest disagreement: annual EPS moved +20.1% against a −31.1% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (46 weeks in) while the P/E sits at the 9th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +75.0% year on year, and 116% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Expleo Solutions Ltd trades at ₹803, in a downtrend and 46 weeks into that stage. That is −9.4% against its own 200-day average. It sits at 27% of a 52-week range of ₹686 to ₹1,113. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (6 weeks and counting).
Today the stock is in a downtrend — week 46 of stage 4, confirmed. At ₹803 it trades −9.4% versus its 200-day average and sits at 27% of its 52-week range (₹686–₹1,113).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved −10% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (6 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Expleo Solutions Ltd trades at 9.2× P/E, near the bottom of its own range — cheaper only 9% of the time. Its long-run median P/E is 15.9×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 9.2× is near the bottom of its own range — cheaper only 9% of the time, against a long-run median of 15.9× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +20.1% against a −31.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −6.8%/yr price move, ~+12.2%/yr came from earnings growth and ~−19.0 pp from the multiple (compressing); over 10y, of the −1.4%/yr price move, ~+9.5%/yr came from earnings growth and ~−10.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Expleo Solutions Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 8 quarters ago at −38.2% and has held its recovery at +75.0% (single-quarter readings), ROCE holding at 25.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.1% | +7.1% | +29.8% | +15.4% |
| Profit | +20.4% | −2.6% | +19.9% | +12.9% |
| EPS | +20.1% | −15.1% | +10.2% | +8.7% |
| Share price | −31.1% | −20.3% | −6.8% | −1.4% |
4-Factor Sector Score
51.4/100 — rank 28 of 63 in IT - Software · 77% evidence confidence
Expleo Solutions Ltd scores 51.4 out of 100 against the 63 companies it is compared with in IT - Software, ranking 28. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 15.4 + 15.7 + 13.9 + 6.4 = 51.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Expleo Solutions Ltd reported ₹286 Cr of revenue in the Mar 26 quarter, +11.7% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 15.4% a year. The last full year, FY26, came in at ₹1,108 Cr. The last four reported quarters add to ₹1,108 Cr.
FY26 revenue came in at ₹1,108 Cr (+8.1% on the year), capping 10 years at 15.4% compound. The latest quarter (Mar 26) printed ₹286 Cr, +11.7% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +8.1% growth against the decade's 15.4% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.1% over the last 4 quarters against +7.2%/yr over the last 8 — stabilising; TTM profit +20.4% vs +16.7%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Expleo Solutions Ltd's operating margin is 15.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0% to 23.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 15.0%, −1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0%–23.0%.
🚨 Why the margin moved: operating margin went −0.7 pp year on year while gross margin went −0.8 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Expleo Solutions Ltd earned ₹42.0 Cr of net profit in the Mar 26 quarter, +75.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹124 Cr. The 10-year compound rate is 12.9%. That is 14.7% of the quarter's revenue. The same quarter a year earlier earned ₹24.0 Cr.
Mar 26 profit was ₹42.0 Cr, +75.0% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹124 Cr (+20.4%), and the 10-year compound rate is 12.9%.
Why profit moved: revenue contributed +11.7% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +20.6% vs revenue +8.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 116% of Expleo Solutions Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹119 Cr of operating cash against ₹124 Cr of profit. After ₹−12.0 Cr of capital spending, ₹131 Cr was left as free cash.
FY26: operating cash of ₹119 Cr against reported profit of ₹124 Cr, leaving free cash of ₹131 Cr after ₹−12.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 116% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 116%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Expleo Solutions Ltd's cash conversion cycle runs 76 days in FY26, up from 74 days in FY21. Capital spending ran ₹26.0 Cr over the last 3 years. At FY26 sales of ₹1,108 Cr each day of that cycle holds about ₹3.0 Cr, so roughly ₹231 Cr sits inside the business at any moment.
FY26: debtors at 76 days (an asset-light business — no inventory to speak of) — for a full cycle of 76 days, looser than FY21's 74.
In money terms: at FY26 sales of ₹1,108 Cr, each day of the cycle holds about ₹3.0 Cr — so the 76-day loop keeps roughly ₹231 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹26.0 Cr over the last 3 fiscal years against ₹101 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Expleo Solutions Ltd earns a ROCE of 25% in FY26. That is up from a trough of 20% in FY24. Return on invested capital clears the cost of that capital by +14.1 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.2% net margin on 1.19× asset turns.
FY26 ROCE is 25%, recovered from a FY24 trough of 20% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 11.2% net margin × 1.19× asset turns × 1.20× balance-sheet leverage ≈ 16.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 26.1% − 12.0% = a +14.1 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Expleo Solutions Ltd carries total debt of ₹8.0 Cr against shareholder equity of ₹776 Cr as of Mar 26, a debt-to-equity of 0.01 — effectively unlevered. On the annual view that ratio went from 0.04 in FY22 to 0.01 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹8.0 Cr against shareholder equity of ₹776 Cr — a debt-to-equity of 0.01. On the annual view, debt-to-equity went from 0.04 (FY22) to 0.01 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 1.7 points of Expleo Solutions Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 0.1% of the company. Foreign institutions moved +0.1 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −1.7 points over 8 quarters to 0.1%; Foreign institutions: +0.1 points over 8 quarters to 0.1%; Promoters: +0.0 points over 8 quarters to 71.0%.
🚨 Why the register moved: domestic institutions drove it (−1.7 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Expleo Solutions Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Coforge LtdCOFORGE | 75.9/100Favorable setup100% evidence | BREAKING OUT | 30.3/35 Revenue 35.7% · PAT 66.5% · OPM change 3 pp 100% evidence | 15.6/25 ROCE 23.5% · OPM 19% 100% evidence | 12.6/20 P/E 39.8× · PEG 0.57 100% evidence | 17.4/20 RS sector 7.8% · RS bench 10.4% · 1Y 1.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 30.3 + 15.6 + 12.6 + 17.4 = 75.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Silver Touch Technologies LtdSILVERTUC | 71.3/100Favorable setup93% evidence | LEADER | 30.6/35 Revenue 21.1% · PAT 86.4% · OPM change 8 pp 100% evidence | 16.9/25 ROCE 28.9% · OPM 22% 100% evidence | 10.2/20 P/E 61.4× · PEG 1.11 65% evidence | 13.6/20 RS sector 54.7% · RS bench 61.9% · 1Y 157%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.6 + 16.9 + 10.2 + 13.6 = 71.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3NINtec Systems LtdNINSYS | 70.8/100Favorable setup76% evidence | LEADER | 20.8/35 Revenue 21.7% · PAT 21.6% · OPM change 8.1 pp 83% evidence | 21.9/25 ROCE 55% · OPM 30.1% 95% evidence | 9.2/20 P/E 45.4× · PEG — 15% evidence | 18.9/20 RS sector 53.9% · RS bench 58.6% · 1Y 84.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 21.9 + 9.2 + 18.9 = 70.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4InfoBeans Technologies LtdINFOBEAN | 67.4/100Favorable setup81% evidence | ASLEEP | 27.0/35 Revenue 35.5% · PAT 60.4% · OPM change 0 pp 95% evidence | 16.8/25 ROCE 29.2% · OPM 21% 95% evidence | 9.5/20 P/E 19× · PEG — 50% evidence | 14.1/20 RS sector 17.4% · RS bench -0.7% · 1Y 18.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 27 + 16.8 + 9.5 + 14.1 = 67.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Sasken Technologies LtdSASKEN | 65.9/100Favorable setup100% evidence | LEADER | 30.8/35 Revenue 67.8% · PAT 67.4% · OPM change 4 pp 100% evidence | 7.7/25 ROCE 9.9% · OPM 9% 100% evidence | 9.6/20 P/E 37.3× · PEG 0.68 100% evidence | 17.8/20 RS sector 15.4% · RS bench 19.1% · 1Y 23.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 7.7 + 9.6 + 17.8 = 65.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Sahana Systems LtdSAHANA | 65.3/100Favorable setup70% evidence | BASING | 21.8/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 19.4/25 ROCE 39.8% · OPM 29% 95% evidence | 14.4/20 P/E 13.2× · PEG — 50% evidence | 9.7/20 RS sector -14.3% · RS bench 3.2% · 1Y -35.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 19.4 + 14.4 + 9.7 = 65.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Cigniti Technologies LtdCIGNITITEC | 64.3/100Mixed-positive evidence79% evidence | 23.4/35 Revenue 14% · PAT 96.1% · OPM change 2 pp 56% evidence | 16.1/25 ROCE 34.1% · OPM 18% 75% evidence | 16.1/20 P/E 11.4× · PEG 0.61 100% evidence | 8.7/20 RS sector -9.5% · RS bench -15% · 1Y -20.5%0 of 1 week ahead to 2026-05-17 100% evidence | |
| Exact sum: 23.4 + 16.1 + 16.1 + 8.7 = 64.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Hypersoft Technologies Ltd539724 | 63.2/100Mixed-positive evidence61% evidence | LEADER | 25.7/35 Revenue 100% · PAT 100% · OPM change 2.9 pp 71% evidence | 12.0/25 ROCE 20.6% · OPM 14% 76% evidence | 8.6/20 P/E 441× · PEG — 15% evidence | 16.9/20 RS sector 81.1% · RS bench 88.7% · 1Y 282.1%12 of 12 weeks ahead 70% evidence |
| Exact sum: 25.7 + 12 + 8.6 + 16.9 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Tech Mahindra LtdTECHM | 63.0/100Mixed-positive evidence94% evidence | TURNING | 20.8/35 Revenue 10.9% · PAT 14.3% · OPM change 3 pp 100% evidence | 16.1/25 ROCE 23.1% · OPM 17% 100% evidence | 10.8/20 P/E 30.4× · PEG 0.76 100% evidence | 15.3/20 RS sector 14.8% · RS bench 9.3% · 1Y 13%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20.8 + 16.1 + 10.8 + 15.3 = 63 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10ASM Technologies Ltd526433 | 62.9/100Mixed-positive evidence65% evidence | TURNING | 23.7/35 Revenue 82.1% · PAT 100% · OPM change -4 pp 83% evidence | 15.5/25 ROCE 27% · OPM 18% 76% evidence | 8.8/20 P/E 118× · PEG — 15% evidence | 14.9/20 RS sector 5.7% · RS bench 43% · 1Y 61.1%10 of 10 weeks ahead 70% evidence |
| Exact sum: 23.7 + 15.5 + 8.8 + 14.9 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Saksoft LtdSAKSOFT | 62.8/100Mixed-positive evidence90% evidence | TURNING | 24.0/35 Revenue 14% · PAT 22% · OPM change 3 pp 88% evidence | 18.7/25 ROCE 25.5% · OPM 18% 100% evidence | 13.5/20 P/E 16.4× · PEG 0.41 100% evidence | 6.6/20 RS sector -21.2% · RS bench -3.3% · 1Y -21.8%6 of 11 weeks ahead 70% evidence |
| Exact sum: 24 + 18.7 + 13.5 + 6.6 = 62.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -21.2% and the one-year return is -21.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Softtech Engineers LtdSOFTTECH | 61.2/100Mixed-positive evidence76% evidence | FADING | 27.8/35 Revenue 39.5% · PAT 100% · OPM change 6.2 pp 83% evidence | 11.7/25 ROCE 6.2% · OPM 21.4% 95% evidence | 8.8/20 P/E 117× · PEG — 15% evidence | 12.9/20 RS sector 12.7% · RS bench 15.9% · 1Y 15.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 27.8 + 11.7 + 8.8 + 12.9 = 61.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Datamatics Global Services LtdDATAMATICS | 60.9/100Mixed-positive evidence90% evidence | TURNING | 20.9/35 Revenue 15.3% · PAT -5.8% · OPM change 6 pp 88% evidence | 17.9/25 ROCE 20.8% · OPM 21% 100% evidence | 8.5/20 P/E 20.6× · PEG 1.08 100% evidence | 13.6/20 RS sector 9.6% · RS bench 0.6% · 1Y -5.4%6 of 10 weeks ahead 70% evidence |
| Exact sum: 20.9 + 17.9 + 8.5 + 13.6 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14R Systems International LtdRSYSTEMS | 60.4/100Mixed-positive evidence96% evidence | BASING | 23.9/35 Revenue 18.3% · PAT 48.3% · OPM change 2 pp 88% evidence | 14.5/25 ROCE 19.5% · OPM 18% 100% evidence | 18.2/20 P/E 13.5× · PEG 0.26 100% evidence | 3.8/20 RS sector -26% · RS bench -24.4% · 1Y -37.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 14.5 + 18.2 + 3.8 = 60.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26% and the one-year return is -37.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 15BLS E-Services LtdBLSE | 58.2/100Mixed-positive evidence71% evidence | LEADER | 19.4/35 Revenue 100% · PAT 16.9% · OPM change -2 pp 83% evidence | 10.5/25 ROCE 17% · OPM 6% 76% evidence | 9.0/20 P/E 47.5× · PEG — 15% evidence | 19.3/20 RS sector 47.6% · RS bench 51.9% · 1Y 62.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 10.5 + 9 + 19.3 = 58.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16String Metaverse Ltd534535 | 56.8/100Mixed-positive evidence78% evidence | ASLEEP | 26.3/35 Revenue 100% · PAT 100% · OPM change 0 pp 83% evidence | 15.4/25 ROCE 41.6% · OPM 10% 76% evidence | 14.7/20 P/E 6.8× · PEG — 50% evidence | 0.4/20 RS sector -67.5% · RS bench -60.8% · 1Y -80.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 26.3 + 15.4 + 14.7 + 0.4 = 56.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -67.5% and the one-year return is -80.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 17Sonata Software LtdSONATSOFTW | 56.7/100Mixed-positive evidence93% evidence | BREAKING OUT | 11.7/35 Revenue 5.4% · PAT 8.9% · OPM change 1 pp 83% evidence | 16.8/25 ROCE 30.7% · OPM 8% 95% evidence | 14.4/20 P/E 17.7× · PEG 0.61 100% evidence | 13.8/20 RS sector -1.1% · RS bench 1.3% · 1Y -21.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 16.8 + 14.4 + 13.8 = 56.7 · Decision use: Price leads the evidence: RS versus the benchmark is 1.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Ksolves India LtdKSOLVES | 56.6/100Mixed-positive evidence87% evidence | ASLEEP | 17.6/35 Revenue 16% · PAT 16.7% · OPM change 3.9 pp 95% evidence | 20.3/25 ROCE 131% · OPM 30.3% 95% evidence | 13.6/20 P/E 18× · PEG — 50% evidence | 5.1/20 RS sector -10% · RS bench -7.2% · 1Y -15.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 20.3 + 13.6 + 5.1 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Infosys LtdINFY | 56.1/100Mixed-positive evidence82% evidence | BASING | 18.2/35 Revenue 11.2% · PAT 11.1% · OPM change 0 pp 95% evidence | 20.0/25 ROCE 40% · OPM 24% 76% evidence | 14.1/20 P/E 14.7× · PEG — 50% evidence | 3.8/20 RS sector -21.2% · RS bench -18.8% · 1Y -25.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 20 + 14.1 + 3.8 = 56.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Xchanging Solutions LtdXCHANGING | 55.0/100Mixed-positive evidence77% evidence | ASLEEP | 21.0/35 Revenue 9.7% · PAT 18% · OPM change 3 pp 83% evidence | 15.3/25 ROCE 18% · OPM 37% 95% evidence | 13.4/20 P/E 12.4× · PEG — 50% evidence | 5.3/20 RS sector -24.4% · RS bench -11.9% · 1Y -27.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 15.3 + 13.4 + 5.3 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21RNIT AI Solutions LtdAUTOPALIND | 54.4/100Thin evidence · provisional51% evidence | 20.5/35 Revenue 59.8% · PAT 66.7% · OPM change 5.1 pp 83% evidence | 14.6/25 ROCE 20.2% · OPM 40.2% 76% evidence | 9.3/20 P/E 39.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 10 weeks ahead 0% evidence | |
| Exact sum: 20.5 + 14.6 + 9.3 + 10 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Dynacons Systems & Solutions LtdDSSL | 53.7/100Mixed-positive evidence83% evidence | LEADER | 15.7/35 Revenue 12.4% · PAT 19.4% · OPM change 0 pp 83% evidence | 16.8/25 ROCE 29.8% · OPM 9% 95% evidence | 7.8/20 P/E 18.5× · PEG — 50% evidence | 13.4/20 RS sector 10.4% · RS bench 14.3% · 1Y 19.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 16.8 + 7.8 + 13.4 = 53.7 · Decision use: Price leads the evidence: RS versus the benchmark is 14.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 23HCL Technologies LtdHCLTECH | 53.5/100Mixed-positive evidence76% evidence | TURNING | 12.6/35 Revenue 12.6% · PAT 2.6% · OPM change 0 pp 95% evidence | 19.0/25 ROCE 30.4% · OPM 20% 76% evidence | 9.5/20 P/E 20.2× · PEG — 50% evidence | 12.4/20 RS sector 9.9% · RS bench -6.4% · 1Y -9.6%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 19 + 9.5 + 12.4 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Tanla Platforms LtdTANLA | 53.2/100Mixed-positive evidence94% evidence | TURNING | 14.4/35 Revenue 13.2% · PAT 9.9% · OPM change 0 pp 100% evidence | 16.4/25 ROCE 26.3% · OPM 16% 100% evidence | 13.1/20 P/E 14.6× · PEG 1.21 100% evidence | 9.3/20 RS sector -12% · RS bench 5.2% · 1Y -9.6%10 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 16.4 + 13.1 + 9.3 = 53.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 25AvenuesAI LtdCCAVENUE | 52.8/100Mixed-positive evidence83% evidence | TURNING | 20.5/35 Revenue 100% · PAT 25.5% · OPM change -2.3 pp 88% evidence | 8.2/25 ROCE 7.7% · OPM 3.7% 100% evidence | 14.9/20 P/E 19.6× · PEG 0.37 65% evidence | 9.2/20 RS sector -2.2% · RS bench -3.6% · 1Y -1.2%5 of 11 weeks ahead 70% evidence |
| Exact sum: 20.5 + 8.2 + 14.9 + 9.2 = 52.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Seshaasai Technologies LtdSTYL | 52.8/100Mixed-positive evidence73% evidence | TURNING | 13.1/35 Revenue 6.7% · PAT 20.6% · OPM change 0 pp 100% evidence | 16.9/25 ROCE 27.7% · OPM 23% 100% evidence | 12.8/20 P/E 21.2× · PEG 0.81 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 10 weeks ahead 0% evidence |
| Exact sum: 13.1 + 16.9 + 12.8 + 10 = 52.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Tata Consultancy Services LtdTCS | 52.5/100Mixed-positive evidence94% evidence | ASLEEP | 11.1/35 Revenue 7.7% · PAT 1.1% · OPM change -1 pp 100% evidence | 22.3/25 ROCE 63% · OPM 26% 100% evidence | 11.8/20 P/E 15.9× · PEG 1.85 100% evidence | 7.3/20 RS sector -4.6% · RS bench -15.1% · 1Y -24.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 11.1 + 22.3 + 11.8 + 7.3 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Expleo Solutions Ltdthis pageEXPLEOSOL | 51.4/100Mixed-positive evidence77% evidence | ASLEEP | 15.4/35 Revenue 8.1% · PAT 20.4% · OPM change -1 pp 83% evidence | 15.7/25 ROCE 24.8% · OPM 15% 95% evidence | 13.9/20 P/E 9.2× · PEG — 50% evidence | 6.4/20 RS sector -13.4% · RS bench -13.1% · 1Y -34.3%5 of 10 weeks ahead 70% evidence |
| Exact sum: 15.4 + 15.7 + 13.9 + 6.4 = 51.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 29IZMO LtdIZMO | 51.2/100Mixed-positive evidence77% evidence | TURNING | 16.2/35 Revenue 26.1% · PAT -2% · OPM change -5 pp 83% evidence | 12.5/25 ROCE 12.6% · OPM 14% 95% evidence | 6.6/20 P/E 31.2× · PEG — 50% evidence | 15.9/20 RS sector 28.9% · RS bench 19.5% · 1Y 161%7 of 10 weeks ahead 70% evidence |
| Exact sum: 16.2 + 12.5 + 6.6 + 15.9 = 51.2 · Decision use: Price leads the evidence: RS versus the benchmark is 19.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 30LTM LtdLTM | 50.8/100Mixed-positive evidence100% evidence | TURNING | 17.1/35 Revenue 13.9% · PAT 10% · OPM change 1 pp 100% evidence | 17.8/25 ROCE 29.6% · OPM 18% 100% evidence | 11.2/20 P/E 23.1× · PEG 1.18 100% evidence | 4.7/20 RS sector -16% · RS bench -13.6% · 1Y -14.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 17.8 + 11.2 + 4.7 = 50.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Wipro LtdWIPRO | 50.3/100Mixed-positive evidence94% evidence | ASLEEP | 13.8/35 Revenue 6.4% · PAT -1.7% · OPM change 0 pp 100% evidence | 14.9/25 ROCE 17.8% · OPM 19% 100% evidence | 13.2/20 P/E 13.8× · PEG 1.4 100% evidence | 8.4/20 RS sector -1.9% · RS bench -18.5% · 1Y -29.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13.8 + 14.9 + 13.2 + 8.4 = 50.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 32Mastek LtdMASTEK | 50.3/100Mixed-positive evidence82% evidence | TURNING | 14.1/35 Revenue 6% · PAT 5% · OPM change 0 pp 95% evidence | 13.8/25 ROCE 18% · OPM 15% 76% evidence | 12.7/20 P/E 13.2× · PEG — 50% evidence | 9.7/20 RS sector -6.7% · RS bench -4.4% · 1Y -24.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 13.8 + 12.7 + 9.7 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33Subex LtdSUBEXLTD | 50.0/100Thin evidence · provisional53% evidence | TURNING | 19.8/35 Revenue -2.3% · PAT 100% · OPM change 31 pp 62% evidence | 8.7/25 ROCE 12.8% · OPM 12.6% 95% evidence | 9.9/20 P/E 21.7× · PEG — 15% evidence | 11.6/20 RS sector — · RS bench 8.4% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 19.8 + 8.7 + 9.9 + 11.6 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Birlasoft LtdBSOFT | 49.4/100Mixed-negative evidence100% evidence | BASING | 19.8/35 Revenue 1.4% · PAT 21.1% · OPM change 4 pp 100% evidence | 13.0/25 ROCE 21.2% · OPM 16% 100% evidence | 14.5/20 P/E 14.2× · PEG 0.62 100% evidence | 2.1/20 RS sector -21.6% · RS bench -19% · 1Y -23.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 13 + 14.5 + 2.1 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Blue Cloud Softech Solutions Ltd539607 | 49.1/100Mixed-negative evidence65% evidence | TURNING | 20.3/35 Revenue 25.7% · PAT 39.5% · OPM change 8 pp 83% evidence | 10.7/25 ROCE 14.2% · OPM 17% 76% evidence | 9.6/20 P/E 29.8× · PEG — 15% evidence | 8.5/20 RS sector -1.9% · RS bench -14.9% · 1Y -35.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.3 + 10.7 + 9.6 + 8.5 = 49.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Hexaware Technologies LtdHEXT | 48.3/100Mixed-negative evidence94% evidence | TURNING | 14.5/35 Revenue 13% · PAT 1.2% · OPM change 4 pp 100% evidence | 17.5/25 ROCE 30.1% · OPM 16% 100% evidence | 10.4/20 P/E 24.2× · PEG 0.81 100% evidence | 5.9/20 RS sector -21.4% · RS bench -9.9% · 1Y -24%6 of 10 weeks ahead 70% evidence |
| Exact sum: 14.5 + 17.5 + 10.4 + 5.9 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Mphasis LtdMPHASIS | 48.1/100Mixed-negative evidence94% evidence | TURNING | 15.3/35 Revenue 13.7% · PAT 9.9% · OPM change -1 pp 100% evidence | 17.1/25 ROCE 22.1% · OPM 18% 100% evidence | 5.6/20 P/E 23.1× · PEG 2.19 100% evidence | 10.1/20 RS sector 0% · RS bench -9.2% · 1Y -10.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 15.3 + 17.1 + 5.6 + 10.1 = 48.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 38Zensar Technologies LtdZENSARTECH | 47.4/100Mixed-negative evidence100% evidence | BASING | 15.8/35 Revenue 8% · PAT 15.3% · OPM change 0 pp 100% evidence | 13.8/25 ROCE 22.8% · OPM 15% 100% evidence | 13.3/20 P/E 14.5× · PEG 1.11 100% evidence | 4.5/20 RS sector -23.7% · RS bench -21.9% · 1Y -36.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 13.8 + 13.3 + 4.5 = 47.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39TechNVision Ventures LtdTECHNVISN | 46.5/100Mixed-negative evidence62% evidence | ASLEEP | 17.0/35 Revenue 18.2% · PAT 90.9% · OPM change -5.7 pp 62% evidence | 8.9/25 ROCE 12.9% · OPM -4.1% 95% evidence | 8.5/20 P/E 12760× · PEG — 15% evidence | 12.1/20 RS sector 32.1% · RS bench -21.9% · 1Y 16.2%0 of 7 weeks ahead 70% evidence |
| Exact sum: 17 + 8.9 + 8.5 + 12.1 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40XT Global Infotech LtdXTGLOBAL | 46.5/100Mixed-negative evidence61% evidence | 18.7/35 Revenue 85.4% · PAT 29.4% · OPM change -6.6 pp 53% evidence | 9.2/25 ROCE 7.5% · OPM 9.5% 71% evidence | 9.4/20 P/E 40.8× · PEG — 50% evidence | 9.2/20 RS sector -1.1% · RS bench -12.7% · 1Y -18.7%2 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 18.7 + 9.2 + 9.4 + 9.2 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Unicommerce eSolutions LtdUNIECOM | 46.4/100Mixed-negative evidence70% evidence | ASLEEP | 14.9/35 Revenue 51.6% · PAT 16.1% · OPM change -4.8 pp 83% evidence | 17.1/25 ROCE 21.1% · OPM 13.4% 95% evidence | 9.1/20 P/E 46.5× · PEG — 15% evidence | 5.3/20 RS sector -14.5% · RS bench -24.2% · 1Y -31.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.9 + 17.1 + 9.1 + 5.3 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 42Capillary Technologies India LtdCAPILLARY | 44.2/100Thin evidence · provisional59% evidence | ASLEEP | 21.6/35 Revenue 22.5% · PAT 271.4% · OPM change -2 pp 88% evidence | 4.0/25 ROCE 3.6% · OPM 16% 100% evidence | 8.6/20 P/E 134× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 21.6 + 4 + 8.6 + 10 = 44.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Magellanic Cloud LtdMCLOUD | 44.0/100Mixed-negative evidence77% evidence | TURNING | 13.3/35 Revenue 17.1% · PAT 11.7% · OPM change -3 pp 83% evidence | 15.4/25 ROCE 19.8% · OPM 26% 95% evidence | 11.9/20 P/E 14.9× · PEG — 50% evidence | 3.4/20 RS sector -54.5% · RS bench -27.4% · 1Y -64.9%5 of 11 weeks ahead 70% evidence |
| Exact sum: 13.3 + 15.4 + 11.9 + 3.4 = 44 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Mindteck (India) LtdMINDTECK | 43.8/100Mixed-negative evidence77% evidence | ASLEEP | 14.6/35 Revenue -4% · PAT 10.3% · OPM change 2 pp 83% evidence | 10.6/25 ROCE 15.1% · OPM 10% 95% evidence | 11.7/20 P/E 18.2× · PEG — 50% evidence | 6.9/20 RS sector -10.1% · RS bench -9.9% · 1Y -6.9%3 of 10 weeks ahead 70% evidence |
| Exact sum: 14.6 + 10.6 + 11.7 + 6.9 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 45Innovana Thinklabs LtdINNOVANA | 38.7/100Mixed-negative evidence77% evidence | ASLEEP | 10.2/35 Revenue 27.9% · PAT -18.2% · OPM change -46.5 pp 83% evidence | 10.0/25 ROCE 16.4% · OPM 9.7% 95% evidence | 9.7/20 P/E 17.8× · PEG — 50% evidence | 8.8/20 RS sector -0.4% · RS bench -22% · 1Y -39.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 10.2 + 10 + 9.7 + 8.8 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4663 Moons Technologies Ltd63MOONS | 38.7/100Mixed-negative evidence62% evidence | TURNING | 16.7/35 Revenue 100% · PAT -17% · OPM change 397 pp 83% evidence | 3.4/25 ROCE -3.7% · OPM -57% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.6/20 RS sector -22.4% · RS bench 26.5% · 1Y -10.7%7 of 11 weeks ahead 70% evidence |
| Exact sum: 16.7 + 3.4 + 10 + 8.6 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 47Allied Digital Services LtdADSL | 38.2/100Mixed-negative evidence62% evidence | ASLEEP | 18.1/35 Revenue 19.9% · PAT 25.8% · OPM change 0.8 pp 62% evidence | 5.5/25 ROCE 7.3% · OPM -3.8% 95% evidence | 10.4/20 P/E 18.1× · PEG — 15% evidence | 4.2/20 RS sector -29.8% · RS bench -19.6% · 1Y -33.4%5 of 10 weeks ahead 70% evidence |
| Exact sum: 18.1 + 5.5 + 10.4 + 4.2 = 38.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 48Kellton Tech Solutions LtdKELLTONTEC | 36.4/100Mixed-negative evidence81% evidence | ASLEEP | 10.4/35 Revenue 9.5% · PAT 9.6% · OPM change -1 pp 95% evidence | 9.5/25 ROCE 15% · OPM 11% 95% evidence | 11.5/20 P/E 8.3× · PEG — 50% evidence | 5.0/20 RS sector -18.8% · RS bench -25.3% · 1Y -55.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 10.4 + 9.5 + 11.5 + 5 = 36.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 49Aurionpro Solutions LtdAURIONPRO | 35.9/100Mixed-negative evidence93% evidence | ASLEEP | 13.5/35 Revenue 14.8% · PAT 5.1% · OPM change -3 pp 100% evidence | 10.7/25 ROCE 16.3% · OPM 17% 100% evidence | 9.9/20 P/E 19.3× · PEG 1.39 65% evidence | 1.8/20 RS sector -29.5% · RS bench -27.8% · 1Y -47.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.5 + 10.7 + 9.9 + 1.8 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 50Moschip Technologies LtdMOSCHIP | 30.3/100Adverse evidence87% evidence | TURNING | 8.1/35 Revenue 8.4% · PAT -33.6% · OPM change -3.9 pp 100% evidence | 6.8/25 ROCE 11% · OPM 8.2% 100% evidence | 3.7/20 P/E 127× · PEG 5.04 65% evidence | 11.7/20 RS sector 1.9% · RS bench -2.2% · 1Y 23.8%9 of 10 weeks ahead 70% evidence |
| Exact sum: 8.1 + 6.8 + 3.7 + 11.7 = 30.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 51Quick Heal Technologies LtdQUICKHEAL | 20.4/100Adverse evidence69% evidence | ASLEEP | 6.2/35 Revenue -6.6% · PAT -80% · OPM change -22.1 pp 71% evidence | 1.6/25 ROCE -4.7% · OPM -39% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.6/20 RS sector -35.1% · RS bench -34% · 1Y -52.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 6.2 + 1.6 + 10 + 2.6 = 20.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 52Covance Softsol Ltd544361 | 66.7/100Thin evidence · provisional49% evidence | 25.7/35 Revenue 43.5% · PAT 100% · OPM change 19.7 pp 62% evidence | 17.9/25 ROCE 31.4% · OPM 23.1% 76% evidence | 10.7/20 P/E 15.3× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 82.1% · 1Y — 25% evidence | |
| Exact sum: 25.7 + 17.9 + 10.7 + 12.4 = 66.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 53Meta Infotech LtdMETA | 54.6/100Thin evidence · provisional21% evidence | 17.1/35 Revenue — · PAT — · OPM change -2 pp 10% evidence | 16.3/25 ROCE 51.1% · OPM 8% 57% evidence | 11.2/20 P/E 13× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -52.4%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 17.1 + 16.3 + 11.2 + 10 = 54.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 54TAC Infosec LtdTAC | 54.2/100Thin evidence · provisional50% evidence | TURNING | 18.1/35 Revenue — · PAT — · OPM change -6 pp 26% evidence | 20.5/25 ROCE 38.1% · OPM 45% 95% evidence | 9.1/20 P/E 46.4× · PEG — 15% evidence | 6.5/20 RS sector -13.2% · RS bench -13.4% · 1Y 12.1%1 of 10 weeks ahead 70% evidence |
| Exact sum: 18.1 + 20.5 + 9.1 + 6.5 = 54.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Exato Technologies Ltd544626 | 52.7/100Thin evidence · provisional33% evidence | 17.1/35 Revenue — · PAT — · OPM change -3.9 pp 32% evidence | 16.1/25 ROCE 26.8% · OPM 10.4% 76% evidence | 9.5/20 P/E 36.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 17.1 + 16.1 + 9.5 + 10 = 52.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 56Unified Data- Tech Solutions LtdUNIFIED | 52.4/100Thin evidence · provisional22% evidence | 15.8/35 Revenue — · PAT — · OPM change -8 pp 15% evidence | 16.9/25 ROCE 47.9% · OPM 13% 57% evidence | 9.7/20 P/E 23.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y 9.4%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 15.8 + 16.9 + 9.7 + 10 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Kody Technolab LtdKODYTECH | 52.3/100Thin evidence · provisional48% evidence | TURNING | 15.2/35 Revenue — · PAT — · OPM change -5 pp 19% evidence | 12.8/25 ROCE 16.8% · OPM 29% 95% evidence | 8.7/20 P/E 121× · PEG — 15% evidence | 15.6/20 RS sector 10.3% · RS bench 66.8% · 1Y 94.4%7 of 10 weeks ahead 70% evidence |
| Exact sum: 15.2 + 12.8 + 8.7 + 15.6 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Trident Techlabs LtdTECHLABS | 46.5/100Thin evidence · provisional40% evidence | 16.2/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 16.2/25 ROCE 26.7% · OPM 27% 71% evidence | 10.8/20 P/E 14.9× · PEG — 15% evidence | 3.3/20 RS sector -50.3% · RS bench -56.5% · 1Y -65.1%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 16.2 + 16.2 + 10.8 + 3.3 = 46.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 59Excelsoft Technologies LtdEXCELSOFT | 46.3/100Thin evidence · provisional43% evidence | ASLEEP | 12.8/35 Revenue — · PAT — · OPM change -11 pp 45% evidence | 13.3/25 ROCE 13.6% · OPM 30% 95% evidence | 10.2/20 P/E 19.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 12.8 + 13.3 + 10.2 + 10 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 60ERP Soft Systems Ltd530909 | 44.8/100Thin evidence · provisional41% evidence | 20.3/35 Revenue 19.1% · PAT 100% · OPM change -1.1 pp 53% evidence | 8.0/25 ROCE 1.6% · OPM 1.7% 57% evidence | 8.9/20 P/E 74.9× · PEG — 15% evidence | 7.6/20 RS sector — · RS bench -47.6% · 1Y -56.7%0 of 12 weeks ahead to 2026-03-29 25% evidence | |
| Exact sum: 20.3 + 8 + 8.9 + 7.6 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 61Veefin Solutions LtdVEEFIN | 43.3/100Thin evidence · provisional33% evidence | 17.0/35 Revenue — · PAT — · OPM change -12.4 pp 5% evidence | 10.4/25 ROCE 6.8% · OPM 20% 57% evidence | 9.3/20 P/E 40.5× · PEG — 15% evidence | 6.6/20 RS sector -7.2% · RS bench -18.7% · 1Y -30.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 17 + 10.4 + 9.3 + 6.6 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 62IDream Film Infrastructure Company Ltd504375 | 41.0/100Thin evidence · provisional30% evidence | 13.5/35 Revenue — · PAT 0% · OPM change — 29% evidence | 5.0/25 ROCE -9.2% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.5/20 RS sector — · RS bench 144.4% · 1Y —4 of 4 weeks ahead 25% evidence | |
| Exact sum: 13.5 + 5 + 10 + 12.5 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 63Orient Technologies LtdORIENTTECH | 33.7/100Thin evidence · provisional45% evidence | ASLEEP | 15.6/35 Revenue — · PAT — · OPM change -5 pp 13% evidence | 2.2/25 ROCE 8.4% · OPM 2.4% 95% evidence | 9.0/20 P/E 47.7× · PEG — 15% evidence | 6.9/20 RS sector -7.1% · RS bench -16.1% · 1Y -11.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 15.6 + 2.2 + 9 + 6.9 = 33.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Expleo Solutions Ltd's share price today?
Expleo Solutions Ltd trades at ₹803, −31.1% over the past year. The company is valued at ₹1,246 Cr. The stock sits at 27% of its 52-week range of ₹686–₹1,113, −9.4% versus its 200-day average. On the tape, the price is in a downtrend, 46 weeks in. — as of 31 July 2026.
What were Expleo Solutions Ltd's latest quarterly results?
Expleo Solutions Ltd reported revenue of ₹286 Cr and net profit of ₹42.0 Cr for the Mar 26 quarter. Revenue rose 11.7% and profit rose 75.0% year on year. Earnings per share were ₹26.85. The operating margin was 15.0%, 1.0 pp lower than a year earlier. — as of 31 July 2026.
What is Expleo Solutions Ltd's revenue?
Expleo Solutions Ltd reported revenue of ₹286 Cr in the Mar 26 quarter, +11.7% year on year. For the full FY26 fiscal year, revenue was ₹1,108 Cr (+8.1%). Over the last 10 years revenue compounded at 15.4% a year. — as of 31 July 2026.
What is Expleo Solutions Ltd's profit?
Expleo Solutions Ltd earned ₹42.0 Cr of net profit in the Mar 26 quarter, +75.0% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹124 Cr. The operating margin ran 15.0% in the latest quarter. — as of 31 July 2026.
What is Expleo Solutions Ltd's market cap?
Expleo Solutions Ltd's market capitalisation is ₹1,246 Cr at a share price of ₹803. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Expleo Solutions Ltd's P/E ratio?
Expleo Solutions Ltd trades at a P/E of 9.2×, at the 9th percentile of its own 10-year range, against a long-run median of 15.9×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Expleo Solutions Ltd pay a dividend?
Not in its latest year — Expleo Solutions Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 7 of its last 13 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Expleo Solutions Ltd overvalued?
On its own history, Expleo Solutions Ltd looks cheap against its own history: its P/E of 9.2× has been cheaper only 9% of the time in 10 years (long-run median 15.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Expleo Solutions Ltd growing?
Yes — Expleo Solutions Ltd is growing: latest-quarter revenue +11.7% year on year, profit +75.0%, and the margin −1.0 pp at 15.0%. The 10-year compound rates are 15.4% (revenue) and 12.9% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Expleo Solutions Ltd performing?
Expleo Solutions Ltd is in a downtrend, 46 weeks in. Its latest quarter's revenue rose 11.7% and profit rose 75.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Expleo Solutions Ltd in?
Improving — profit growth bottomed 8 quarters ago at −38.2% and has held its recovery at +75.0% (single-quarter readings), ROCE holding at 25.0%. The read comes from the last 12 quarters of growth (revenue growth +11.7% latest, profit growth +75.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Expleo Solutions Ltd in an uptrend?
No — the price is in a downtrend (week 46 of stage 4), trading −9.4% versus its 200-day average and at 27% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Expleo Solutions Ltd beating the market?
Not lately — on a trailing-13-week view Expleo Solutions Ltd is currently behind the NIFTY 500 (6 weeks and counting; last ahead the week of 2026-06-25), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved −10% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will Expleo Solutions Ltd's share price go up?
This page publishes no price forecast for Expleo Solutions Ltd. What it measures instead: the share price is ₹803, the price is in a downtrend 46 weeks in. Its P/E of 9.2× sits at the 9th percentile of its own 10-year range. — as of 31 July 2026.
Who owns Expleo Solutions Ltd?
Promoters hold 71.0% of Expleo Solutions Ltd, foreign institutions 0.1%, domestic institutions 0.1% and the public 28.7% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 1.7 points over 8 quarters. — as of 31 July 2026.
Does Expleo Solutions Ltd have too much debt?
No — Expleo Solutions Ltd's debt-to-equity is 0.01, and operating profit covers the interest bill 85×. FY26 borrowings were ₹8.0 Cr against equity of ₹777 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Expleo Solutions Ltd's capex?
Expleo Solutions Ltd spent ₹26.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹−12.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Expleo Solutions Ltd's cash flow?
Expleo Solutions Ltd generated ₹119 Cr of operating cash flow in FY26 and ₹131 Cr of free cash flow after ₹−12.0 Cr of capital spending. Reported profit that year was ₹124 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Expleo Solutions Ltd's profit real cash?
Yes — over the last 3 fiscal years, 116% of Expleo Solutions Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹119 Cr against reported profit of ₹124 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Expleo Solutions Ltd in its business cycle?
Expleo Solutions Ltd's FY26 operating margin was 15.0%, against a 13-year band of 15.0%–23.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 15.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Expleo Solutions Ltd story?
The sharpest disagreement: annual EPS moved +20.1% against a −31.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Expleo Solutions Ltd a stock worth studying right now?
This is not investment advice. The machine read: Expleo Solutions Ltd's earnings have outrun its stock. EPS grew +20.1% in a year against a −31.1% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.